Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort
Posted inCritical Care news Respiratory

Frailty Amplifies Mortality Risk Across the PaO2/FiO2 Spectrum: Insights from a 497,185‑Patient ANZICS Cohort

In a 497,185‑patient registry study, frailty (CFS ≥5) was common and associated with substantially higher in‑hospital mortality across all severities of acute hypoxemic respiratory failure (AHRF). The relationship between PaO2/FiO2 and death was nonlinear and distinctly separated by frailty category.
Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT
Posted inAnesthesiology General Surgery news Rehabilitation Medicine

Home-Based Prehabilitation Did Not Reduce Disability or Complications in Older Adults with Frailty: Results of a Pragmatic Multicenter RCT

A pragmatic multicenter randomized trial found that coach-supported, home-based multimodal prehabilitation before elective noncardiac surgery did not reduce 30-day postoperative disability or in-hospital complications in older adults with frailty; higher adherence signaled possible benefit for disability outcomes.
Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen
Posted inHematology-Oncology news Oncology Specialties

Optimizing Treatment in Frail Elderly with Newly Diagnosed Multiple Myeloma: Insights from the IFM2017-03 Trial on Dexamethasone-Sparing Daratumumab and Lenalidomide Regimen

The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious adverse events.